Our results further strengthen the hypothesis that VCP gain-of-function variants are causal for the disease pathogenesis [15, 18, 19] and that inhibition of VCP activity has translational potential, not only for cancer but also for VCP-associated myopathy. This evidence concerns the gene VCP and myopathy.